Bryn Mawr Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bryn Mawr Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$330K	Buy	5,434 +220	+4%	+$12.8K	0.02%	337
2025 Q4	$281K	Buy	5,214 +29	+0.6%	+$1.4K	0.01%	362
2025 Q3	$234K	Buy	5,185 +500	+11%	+$23.4K	0.01%	400
2025 Q2	$217K	Sell	4,685 -2,969	-39%	-$146K	0.01%	392
2025 Q1	$467K	Buy	7,654 +64	+0.8%	+$3.73K	0.03%	264
2024 Q4	$429K	Buy	7,590 +318	+4%	+$17.8K	0.02%	293
2024 Q3	$376K	Hold	7,272	–	–	0.02%	321
2024 Q2	$302K	Hold	7,272	–	–	0.02%	333
2024 Q1	$394K	Hold	7,272	–	–	0.02%	311
2023 Q4	$373K	Sell	7,272 -3,628	-33%	-$190K	0.02%	308
2023 Q3	$633K	Buy	10,900 +4,514	+71%	+$277K	0.04%	254
2023 Q2	$408K	Buy	6,386 +2,542	+66%	+$170K	0.04%	221
2023 Q1	$266K	Sell	3,844 -109	-3%	-$7.69K	0.03%	240
2022 Q4	$284K	Buy	+3,953	New	+$298K	0.03%	235
2021 Q3	–	Sell	-3,188	Closed	-$213K	–	104
2021 Q2	$213K	Buy	+3,188	New	+$208K	0.1%	92
2021 Q1	–	Sell	-3,457	Closed	-$214K	–	96
2020 Q4	$214K	Hold	3,457	–	–	0.11%	89
2020 Q3	$208K	Sell	3,457 -295	-8%	-$17.8K	0.12%	82
2020 Q2	$221K	Hold	3,752	–	–	0.14%	75
2020 Q1	$209K	Sell	3,752 -266	-7%	-$16.3K	0.14%	70
2019 Q4	$258K	Buy	+4,018	New	+$230K	0.19%	74
2018 Q4	–	Sell	-3,854	Closed	-$239K	–	78
2018 Q3	$239K	Sell	3,854 -743	-16%	-$44.1K	0.2%	72
2018 Q2	$254K	Buy	4,597 +28	+0.6%	+$1.51K	0.22%	65
2018 Q1	$289K	Sell	4,569 -1,027	-18%	-$66.1K	0.26%	59
2017 Q4	$357K	Hold	5,596	–	–	0.47%	42
2017 Q3	$357K	Buy	5,596 +5	+0.1%	+$292	0.37%	50
2017 Q2	$312K	Buy	5,591 +713	+15%	+$38.8K	0.35%	47
2017 Q1	$265K	Buy	4,878 +449	+10%	+$24.6K	0.27%	61
2016 Q4	$259K	Buy	+4,429	New	+$242K	0.26%	60

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bryn Mawr Capital Management's BMY Position: Q1 2026 in Review

Bryn Mawr Capital Management increased its Bristol-Myers Squibb (BMY) stake by 4.2% in Q1 2026, buying an estimated $12.8K and bringing the position to 5,434 shares worth $330K. The position accounts for 0.02% of the portfolio, ranked #337.

Bryn Mawr Capital Management first reported a position in BMY in Q4 2016 and has held it in 28 quarters since. The position peaked at $633K in Q3 2023. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Bryn Mawr Capital Management held 5,434 shares of Bristol-Myers Squibb worth $330K as of Q1 2026.
Bryn Mawr Capital Management bought 220 Bristol-Myers Squibb shares in Q1 2026, an estimated $12.8K.
Bristol-Myers Squibb made up 0.02% of Bryn Mawr Capital Management's portfolio in Q1 2026, its #337 holding.
Bryn Mawr Capital Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 28 quarters since.
Bryn Mawr Capital Management's Bristol-Myers Squibb position peaked at $633K in Q3 2023.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.